GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents
Phase 2
Completed
- Conditions
- Infections, Meningococcal
- Interventions
- Biological: Meningococcal ABCWY VaccineBiological: Meningococcal B Recombinant vaccine
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 604
- Registration Number
- NCT02946385
- Locations
- 🇵🇱
GSK Investigational Site, Wroclaw, Poland
Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT02939846
A Bite Force Study Comparing Two New Test Adhesives With Currently Marketed Denture Adhesive
Not Applicable
Completed
- Conditions
- Denture Retention
- Interventions
- Device: Test Product 1Other: Negative ControlDevice: Test Product 2Device: Reference Product
- First Posted Date
- 2016-10-19
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT02937870
- Locations
- 🇺🇸
GSK Investigational Site, Bloomfield, New Jersey, United States
To Investigate the Gingivitis Efficacy of a Stannous Fluoride Dentifrice in a Chinese Population
Not Applicable
Completed
- Conditions
- Gingivitis
- Interventions
- Other: Sodium monofluorophosphateOther: Stannous fluoride
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2019-06-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 128
- Registration Number
- NCT02937636
- Locations
- 🇨🇳
GSK Investigational Site, Shanghai, China
To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH)
Not Applicable
Completed
- Conditions
- Dentin Sensitivity
- Interventions
- Device: Dissolvable polymer strip containing Novamin (calcium sodium phosphosilicate)
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2018-01-29
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 126
- Registration Number
- NCT02937623
- Locations
- 🇺🇸
GSK Investigational Site, Las Vegas, Nevada, United States
Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)
Phase 1
Terminated
- Conditions
- Myelodysplastic SyndromeMyelodysplastic Syndromes
- Interventions
- First Posted Date
- 2016-10-11
- Last Posted Date
- 2019-05-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 7
- Registration Number
- NCT02929498
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
Evaluation of a Experimental Denture Adhesive to Prevent Food Ingress
Not Applicable
Completed
- Conditions
- Denture Retention
- Interventions
- Device: Experimental Denture AdhesiveDevice: Reference (Marketed) Denture Adhesive
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 83
- Registration Number
- NCT02928380
- Locations
- 🇺🇸
GSK Investigational Site, Fort Wayne, Indiana, United States
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects
Phase 1
Completed
- Conditions
- Lupus Erythematosus, Cutaneous
- Interventions
- Drug: GSK2646264 1%Drug: Placebo
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 11
- Registration Number
- NCT02927457
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza
Phase 2
Terminated
- Conditions
- Virus Diseases
- Interventions
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 10
- Registration Number
- NCT02927431
- Locations
- 🇸🇪
GSK Investigational Site, Lund, Sweden
A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Drug: PlaceboBiological: RSV (GSK3389245A) low dose formulation vaccineBiological: RSV (GSK3389245A) middle dose formulation vaccineBiological: RSV (GSK3389245A) high dose formulation vaccine
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2021-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 107
- Registration Number
- NCT02927873
- Locations
- 🇨🇳
GSK Investigational Site, Taoyuan, Taiwan
© Copyright 2025. All Rights Reserved by MedPath